Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
IRD
SellHot AirOpus Genetics, Inc. · Healthcare · United States · $307M · Avg Vol: $19M/d
COMPANY DESCRIPTION
Opus Genetics is a gene therapy company focused on developing therapies for inherited retinal diseases (IRDs), addressing unmet medical needs in conditions like Leber Congenital Amaurosis. Its competitive moat is based on pioneering scientific research, a targeted pipeline addressing specific genetic mutations, and potential first-in-class treatments for severe and rare ophthalmic conditions. Opus Genetics is a highly specialized biotech firm, aiming to be a leader in the nascent field of gene therapy for retinal degenerations.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 39.9M | 19.0M | 11.0M | 14.2M | -29.1% | 9.9M | 12.4M | 12.9M | -4.7% |
| EPS | — | 0.23 | -0.13 | -0.82 | -0.80 | — | -1.29 | -0.96 | -0.74 | — |
| Shares | — | 82.6M | 82.6M | 82.6M | 69.9M | -15.3% | 83.2M | — | — | — |
| Debt | 0.5M | — | — | — | 1.1M | 20.4% | — | — | — | — |
| Equity | — | 46.2M | 49.9M | 6.7M | 15.3M | -30.8% | — | — | — | — |
| Op CF | — | 14.3M | -1.1M | -25.6M | -35.3M | — | -40.7M | — | — | — |
| Inv CF | — | 0 | 0 | 1.2M | 0 | — | — | — | — | — |
| Fin CF | — | 3.8M | 9.0M | 4.2M | 50.0M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of IRD are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| IRD | Opus Genetics, Inc.(you) | $307M | 22 | Sell |
| FATE | Fate Therapeutics, Inc. | $291M | 21 | Sell |
| OBIO | Orchestra BioMed Holdings, Inc. | $312M | 19 | Strong Sell |
| SABS | SAB Biotherapeutics, Inc. | $345M | 23 | Sell |
| IMRX | Immuneering Corporation | $323M | 19 | Strong Sell |
| VNDA | Vanda Pharmaceuticals Inc. | $320M | 18 | Strong Sell |
| FULC | Fulcrum Therapeutics, Inc. | $294M | 17 | Strong Sell |
| ALXO | ALX Oncology Holdings Inc. | $277M | 17 | Strong Sell |
| BNTC | Benitec Biopharma Inc. | $428M | 23 | Sell |
| ZNTL | Zentalis Pharmaceuticals, Inc. | $360M | 17 | Strong Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.3%